Format

Send to

Choose Destination
Pediatr Clin North Am. 2017 Dec;64(6):1197-1207. doi: 10.1016/j.pcl.2017.08.001.

Approaching Current and New Drug Therapies for Pediatric Asthma.

Author information

1
Section of Allergy and Immunology, Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, 13123 East 16th Avenue, Aurora, CO 80045, USA. Electronic address: william.anderson@childrenscolorado.org.
2
The Breathing Institute, Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, 13123 East 16th Avenue, Aurora, CO 80045, USA.

Abstract

As new therapies for pediatric asthma are approved by the Food and Drug Administration, clinicians should be aware of their benefits and limitations. Accompanying these therapies are potential obstacles, including the delivery of inhaled therapies and age-specific issues regarding implementation and adherence. New insights are being added to well-established controller medications, including inhaled corticosteroids and long-acting β-agonists, while new medications previously approved in adults, including tiotropium and biologics, are now being evaluated for use in children. These drugs can be useful additive therapies to treat patients who are currently not responding to guidelines-based therapy.

KEYWORDS:

Adherence; Biologics; Drug delivery; Drug development; Inhaled corticosteroids; Long-acting β-agonists; Omalizumab; Tiotropium

PMID:
29173780
DOI:
10.1016/j.pcl.2017.08.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science Icon for University of Colorado, Health Sciences Library
Loading ...
Support Center